KEYTRUDA Drug Profile

Summary for Tradename: KEYTRUDA

High Confidence Patents:	18
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for KEYTRUDA

Recent Clinical Trials for KEYTRUDA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Bio-Thera Solutions	PHASE1
Shanghai Henlius Biotech	PHASE1
Innovent Biologics (Suzhou) Co. Ltd.	PHASE2

See all KEYTRUDA clinical trials

Pharmacology for KEYTRUDA

Mechanism of Action	Programmed Death Receptor-1-directed Antibody Interactions
Established Pharmacologic Class	Programmed Death Receptor-1 Blocking Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for KEYTRUDA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for KEYTRUDA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2038-09-27	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2037-11-13	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2040-12-22	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2040-12-22	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2040-12-22	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2041-09-02	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2041-06-22	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for KEYTRUDA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2036-06-24	Patent claims search
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2035-02-04	Patent claims search
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2035-08-27	Patent claims search
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2035-06-16	Patent claims search
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2037-07-25	Patent claims search
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2037-03-27	Patent claims search
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514		2036-12-21	Patent claims search

International Patents for KEYTRUDA

Country	Patent Number	Estimated Expiration
South Korea	102031020
Hungary	S1500071
Australia	2017245352
Japan	2017112999
Portugal	3130347
South Korea	20190116563
China	106999582

Supplementary Protection Certificates for KEYTRUDA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
300788	Netherlands		PRODUCT NAME: PEMBROLIZUMAB; REGISTRATION NO/DATE: EU/1/15/1024/001 20150721
SPC/GB15/084	United Kingdom		PRODUCT NAME: PEMBROLIZUMAB; REGISTERED: UK EU/1/15/1024 (NI) 20150721
569	Finland
C01537878/02	Switzerland		PRODUCT NAME: PEMBROLIZUMAB; REGISTRATION NO/DATE: SWISSMEDIC 65440 10.09.2015
2015C/080	Belgium		PRODUCT NAME: GEHUMANISEERD MONOCLONAAL ANTI-PROGRAMMED CELL DEATH-1 (PD-1) ANTILICHAAM MET LICHTE KETEN CDRS SEQ ID NOS:15, 16 EN 17 EN ZWARE KETEN CDRS SEQ ID NOS:18, 19 EN 20, IN HET BIJZONDER PEMBROLIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/15/1024/001 20150721
1691001-0	Sweden		PRODUCT NAME:PEMBROLIZUMAB; FIRST MARKETING AUTHORIZATION NUMBER SE: EU/1/15/1024, 2015-07-21
300789	Netherlands		PRODUCT NAME: PEMBROLIZUMAB; REGISTRATION NO/DATE: EU/1/15/1024 20150721

Market Dynamics and Financial Trajectory for KEYTRUDA

Last updated: March 31, 2026

What Is Keytruda, and What Are Its Market Positions?

Keytruda (pembrolizumab) is a PD-1 inhibitor developed by Merck & Co. It received FDA approval in 2014 for melanoma and expanded to multiple cancer indications, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, and gastric cancer. It is classified as an immune checkpoint inhibitor.

As of 2023, Keytruda held the top position among oncology drugs based on global sales. It is available in more than 120 countries with approvals spanning 30+ indications. It competes primarily with drugs such as Bristol-Myers Squibb’s Opdivo (nivolumab) and newer immunotherapies.

What Are the Key Market Drivers?

1. Expanding Indications: Continuous clinical trials lead to approvals in additional cancer types. The drug is approved for 30+ indications globally as of 2023, up from 22 in 2020[1].

2. Growing Oncology Market: The global oncology drug market reached $147 billion in 2022, with a compound annual growth rate (CAGR) of 7.5% (2018–2022)[2].

3. Combination Approaches: Use with chemotherapies, targeted therapies, and other immunotherapies enhances efficacy, making Keytruda a versatile component in treatment regimens.

4. Regulatory Approvals in Early-Stage Disease: Trials showing benefits in adjuvant and neoadjuvant settings increase long-term sales potential.

5. Increased Adoption in Developing Markets: Rising cancer prevalence and healthcare infrastructure expansion bolster sales in China, India, and Southeast Asia.

6. Pricing and Reimbursement: Price increases in certain markets and negotiated reimbursement models influence revenue growth.

How Do Competitive Dynamics Affect Market Share?

• Bristol-Myers Squibb’s Opdivo: A direct competitor with a similar multiple-indication profile. Market share in lung and melanoma indications is closely contested.
• Emerging Checkpoint Inhibitors: New agents are entering early-phase trials, potentially disrupting the market.
• Biosimilars: As patents expire, biosimilars could lower prices and reduce margins.

How Has the Financial Trajectory Evolved?

Historical Financial Data

Year	Global Sales (USD billion)	Year-over-Year Change	Indication Expansion	Key Sources of Revenue
2018	7.2	—	FDA approvals for melanoma, bladder	Oncology, biomarker tests
2019	7.9	+9.7%	Additional approvals for lung, gastric	Oncology primarily
2020	11.1	+40.5%	Expanded in adjuvant setting	Oncology, royalty licensing
2021	15.3	+37.8%	Several new indications	Oncology, licensing fees
2022	17.8	+16.3%	Continued indication growth	Oncology, diagnostics

Source: Merck financial reports and industry analyses[3][4]

Supply chain costs, R&D investments, and competitive pressures influence profit margins. The company has maintained high margins, with operating margins around 50% in recent years.

Revenue Forecasts (2023-2027)

Projection models estimate Keytruda’s sales could grow at a CAGR of 10% to 12% annually, reaching approximately $40 billion by 2027[2].

Key variables influencing forecasts include:

• Approved new indications in lung, melanoma, and head & neck.
• Regulatory decisions in China, India, and emerging markets.
• Expansion into earlier disease stages.
• Competitive landscape stability.

How Do Regulations and Patents Influence Revenue?

Patents for Keytruda primarily expire in the late 2020s, with the US patent expiring in 2028, though patent challenges could extend exclusivity[5].

Regulatory pathways for biosimilar approval might introduce pressures starting around 2028, although current biosimilar developments, mainly in Europe and China, are limited.

What Are the Risks and Opportunities?

Risks:

• Patent expiry and biosimilar entry reduce pricing power.
• New therapies outperforming or replacing immune checkpoint inhibitors.
• Regulatory delays or rejections in key markets.

Opportunities:

• Clinical trials in early-stage cancers expanding approved use.
• Combination therapies increasing overall efficacy.
• Growth in emerging markets with increasing cancer prevalence.

Key Takeaways

• Keytruda leads the cancer immunotherapy market, driven by broad indications and strong clinical pipeline.
• Its sales have grown from $7.2 billion in 2018 to nearly $18 billion in 2022, with forecasts suggesting $40 billion by 2027.
• Market share remains robust amid fierce competition from Opdivo and other emerging therapies.
• Patent expiration and biosimilar entry pose future pricing and revenue risks.
• Expansion into early-stage cancer settings and emerging markets presents growth opportunities.

FAQs

Q1: When will Keytruda face biosimilar competition?
A1: Biosimilars are expected around 2028, contingent on patent challenges and regional approval timelines.

Q2: What new indications are most promising for Keytruda?
A2: Adjuvant lung and melanoma settings, along with head and neck cancers, are rapidly expanding.

Q3: How does Keytruda compare to Opdivo in market share?
A3: As of 2023, Keytruda holds approximately 70% of the PD-1 market, with Opdivo at 25%, globally[6].

Q4: What impact do regulatory decisions in China have?
A4: China’s approvals significantly enhance revenue potential, with local reimbursement policies directly affecting sales.

Q5: How does combination therapy influence sales?
A5: Combining Keytruda with chemotherapy or targeted agents increases efficacy and broadens use, elevating sales volumes.

---

References

1. Merck & Co. (2023). Keytruda product information.
2. Grand View Research. (2023). Oncology drug market size and forecast.
3. Merck Annual Reports. (2018–2022).
4. EvaluatePharma. (2023). Oncology drugs sales analysis.
5. U.S. Patent and Trademark Office. (2023). Keytruda patents.
6. IQVIA. (2023). Market share analysis of PD-1 inhibitors.